HELX.US Franklin Genomic Advancements ETF
- Total assets
- 34.8M
- Expense ratio
- 0.50%
- Dividend yield
- 0.32%
- 1-year return
- +25.36%
- Holdings
- 65
- Since
- 2020
Fund data as reported by the issuer, updated Nov 15, 2026. Total assets are in the fund's base currency.
What does HELX.US invest in?
- Mostly US stocks (94.0%)
- Largest sector: Healthcare (96.9%)
- Largest region: North America (94.1%)
- Top 3 holdings: 21.9% of the fund
Asset allocation
- US stocks 94.0%
- Non-US stocks 4.8%
- Cash 0.1%
Top holdings
- Natera Inc 8.37%
- Guardant Health Inc 8.28%
- Adaptive Biotechnologies Corp 5.23%
- Krystal Biotech Inc 4.81%
- Ligand Pharmaceuticals Incorporated 4.60%
Franklin Genomic Advancements ETF performance
Sharpe ratio 0.84- This year
- +20.30%
- 1 year
- +25.36%
- 3 years
- +18.63%
- 5 years
- -2.59%
Volatility 19.5% over 1 year and 19.8% over 3 years. Moderate, similar to a broad stock index.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
HELX.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About Franklin Genomic Advancements ETF
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Full fund profileFranklin Genomic Advancements ETF top holdings
46.8% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Natera Inc NTRA.US | Healthcare | United States | 8.37% |
| Guardant Health Inc GH.US | Healthcare | United States | 8.28% |
| Adaptive Biotechnologies Corp ADPT.US | Healthcare | United States | 5.23% |
| Krystal Biotech Inc KRYS.US | Healthcare | United States | 4.81% |
| Ligand Pharmaceuticals Incorporated LGND.US | Healthcare | United States | 4.60% |
| BridgeBio Pharma Inc BBIO.US | Healthcare | United States | 3.53% |
| Twist Bioscience Corp TWST.US | Healthcare | United States | 3.12% |
| Eli Lilly and Company LLY.US | Healthcare | United States | 2.99% |
| United Therapeutics Corporation UTHR.US | Healthcare | United States | 2.97% |
| Medpace Holdings Inc MEDP.US | Healthcare | United States | 2.85% |
The 10 largest of 65 holdings.
HELX.US sector exposure
- Healthcare96.9%
- Financial Services2.2%
- Technology0.7%
- Basic Materials0.4%
Share of the stocks in the fund.
HELX.US regional exposure
- North America94.1%
- Europe Developed2.7%
- Asia Developed1.1%
- United Kingdom1.1%
Share of the stocks in the fund.
Company size
Average market cap 18.3B- Mega cap4.1%
- Big cap8.9%
- Medium cap33.8%
- Small cap44.5%
- Micro cap4.0%
Franklin Genomic Advancements ETF fund profile
- Fund name
- Franklin Genomic Advancements ETF
- Ticker
- HELX.US
- Exchange
- USA Stocks
- Issuer
- Franklin Templeton, Inc
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Feb 25, 2020
- Trading currency
- USD
- Expense ratio
- 0.50%
- Annual turnover
- 0.3%
About Franklin Genomic Advancements ETF
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.